Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

Paiva, Bruno; Manrique, Irene; Rytlewski, Julie; Campbell, Timothy; Kazanecki, Christian C.; Martin, Nathan; Anderson, Larry D.; Berdeja, Jesús G.; Lonial, Sagar; Raje, Noopur S.; Lin, Yi; Moreau, Philippe; San-Miguel, Jesús F.; Munshi, Nikhil C.; Kaiser, Shari M.

doi:10.1158/2643-3230.25062079.v1

bcd-23-0044_figure_s2_suppsf2.docx (130.51 kB)

Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

journal contribution

posted on 2024-01-25, 15:00 authored by Bruno Paiva, Irene Manrique, Julie Rytlewski, Timothy Campbell, Christian C. Kazanecki, Nathan Martin, Larry D. Anderson, Jesús G. Berdeja, Sagar Lonial, Noopur S. Raje, Yi Lin, Philippe Moreau, Jesús F. San-Miguel, Nikhil C. Munshi, Shari M. Kaiser

Landmark PFS

Funding

Celgene (Celgene Corporation)

History

ARTICLE ABSTRACT

The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus